Compare · CI vs DMTK
CI vs DMTK
Side-by-side comparison of The Cigna Group (CI) and DermTech Inc. (DMTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and DMTK operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $77.37B, about 232.9x DMTK ($332.2M).
- CI has hit the wire 14 times in the past 4 weeks while DMTK has been quiet.
- CI has more recent analyst coverage (25 ratings vs 5 for DMTK).
- Company
- The Cigna Group
- DermTech Inc.
- Price
- $275.55-1.49%
- $0.10-11.65%
- Market cap
- $77.37B
- $332.2M
- 1M return
- +1.90%
- -
- 1Y return
- -17.71%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 5
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
DermTech Inc.
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Latest CI
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
- Director Ross Kimberly A. was granted 782 shares, increasing direct ownership by 17% to 5,294 units (SEC Form 4)
- Director Hennigan Michael J was granted 782 shares, increasing direct ownership by 138% to 1,350 units (SEC Form 4)
- Director Ozuah Philip was granted 782 shares, increasing direct ownership by 43% to 2,583 units (SEC Form 4)
- Director Wiseman Eric C was granted 782 shares, increasing direct ownership by 3% to 23,940 units (SEC Form 4)
Latest DMTK
- Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- DermTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- S&P 500 Edges Higher; America's Car-Mart Shares Tumble After Q4 Earnings
- Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session